13th Annual Global Embolization Symposium & Technologies
Purpose : To evaluate the safety and efficacy of prostatic artery embolization (PAE) using 300-500μm particles (Embosphere, Merit) versus 400±75μm compressibile microspheres (Hydropearl, Terumo) in the treatment of patients with symptomatic benign prostatic hyperplasia (BPH).
Material and Methods : Over a period of 3-year, 75 patients with lower urinary tract symptoms (LUTS) secondary to BPH were treated with 300-500μm Embosphere (group A = 50) or 400±75μm Hydropearl (group B = 25). Mean follow-up period time was 23 months (range 10-36). Outcome measurements evaluated were procedure-related pain, International Prostate Symptom Score (IPSS), quality of life questionnaire (QOL) and International Index of Erectile Function (IIEF).
Results : Mean follow-up period was greater in group A (24±12months) than group B (12±6 months). No differences between groups regarding pain and clinical score were recorded at 6 and 12 months of follow-up. LUTS recurrence rate were 4% in group A and 8% in group B.
Conclusions : PAE with 300-500μm Embosphere and 400±75μm Hydropearl are equally effective in the treatment of benign prostatic hyperplasia.